Treatments Archives - Clinical Pain Advisor


FDA Approves Ubrogepant Tablets for Acute Treatment of Migraine

The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine with or without aura in adults. The approval was supported by two pivotal phase 3, randomized, double-blind, placebo-controlled trials (ACHIEVE I and ACHIEVE II) that evaluated the efficacy,…

Next post in Migraine & Headache